Default company panoramic image
5c9c878b 9634 4f6d 956a c5ead082c392

MAX BioPharma

MAX BioPharma develops therapeutic agents that modulate Hedgehog signaling to regulate tissue regeneration and tumorigenesis.

  • Stage Not Set
  • Industry Not Set
  • Location Los Angeles, CA, USA
  • Currency USD

Company Summary

MAX BioPharma uses proprietary small molecule oxysterols in developing novel treatments for specific disease processes. We have focused on developing new therapies for stimulation of bone formation in procedures such as spinal fusion and fracture healing, and for disorders such as osteoporosis. We have also initiated the development of a novel class of anti-tumorigenic oxysterols that inhibit the growth of a variety of human tumor cells.

Team

  • Default avatar
    Farhad Parhami
    Founder

    Farhad Parhami was trained as an Experimental Pathologist in the Department of Pathology at UCLA. His training and experience include molecular and cellular biology, lipid metabolism, inflammation, and bone and vascular biology. In 1996 he obtained a faculty position and currently holds the title of Professor-in-Residence in the Department of Medicine at UCLA.

  • Default avatar
    Michael E Jung
    Co-Founder

    Michael Jung is a Distinguished Professor in the Department of Chemistry & Biochemistry at UCLA. He received his BA from Rice University in 1969 and his Ph.D. from Columbia University in 1973, both in Chemistry. After a one-year NATO Postdoctoral fellowship at the Eidgenossische Technische Hochschule (ETH) in Zurich, he started his career at UCLA in 1974. He is an expert in synthetic organic chemistry and especially synthetic medicinal chemistry.

  • Default avatar
    William H Matsui
    Co-Founder

    William Matsui is Associate Professor in the Department of Oncology at Johns Hopkins University School of Medicine. He received his A.B. from Harvard in Biochemistry in 1989, and his M.D. in 1995 from UCSF School of Medicine. He completed residency in internal medicine at the University of Washington in Seattle and clinical fellowship in Oncology at Johns Hopkins. Dr. Matsui is an expert in the development of novel therapeutics in oncology.